FARMADURA XL
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
22-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DOXAZOSIN MESILATE
Available from:
Pfizer Healthcare Ireland
Dosage:
8 Milligram
Pharmaceutical form:
Tablet Prolonged Release
Authorization date:
2011-03-11
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Farmadura XL 8mg Prolonged -release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 8mg doxazosin (as mesilate).
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Prolonged -Release Tablet.
Farmadura XL 8mg prolonged - release tablets are white round, biconvex shaped tablets with an orifice on one side,
marked ‘CXL8’.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Farmadura XL is indicated for the treatment of hypertension and can be used as a sole agent to control blood pressure
in hypertensive patients.
In patients inadequately controlled on single antihypertensive therapy, Farmadura XL may be used in combination with
a thiazide diuretic, beta-adrenoceptor blocking agent, calcium antagonist or an angiotensin-converting enzyme
inhibitor.
4.2 Posology and method of administration
The initial dose of Farmadura XL is 4mg once daily. A significant number of patients will be controlled on this dose. If
necessary, the dosage may be increased to 8mg once daily according to patient response.
The maximum recommended dose is 8mg once daily.
Farmadura XL can be taken with or without food.
The tablets shou
Read the complete document
